| human | Q5 |
| P496 | ORCID iD | 0000-0002-5004-0364 |
| P734 | family name | Visakorpi | Q35149623 |
| Visakorpi | Q35149623 | ||
| Visakorpi | Q35149623 | ||
| P735 | given name | Tapio | Q3817554 |
| Tapio | Q3817554 | ||
| P463 | member of | Finnish Academy of Science and Letters | Q666410 |
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | male | Q6581097 |
| Q94551015 | Q94551015 |
| Q73339480 | 5q11, 8p11, and 10q22 are recurrent chromosomal breakpoints in prostate cancer cell lines |
| Q48520586 | A Four-kallikrein Panel and β-Microseminoprotein in Predicting High-grade Prostate Cancer on Biopsy: An Independent Replication from the Finnish Section of the European Randomized Study of Screening for Prostate Cancer |
| Q37269442 | A comprehensive repertoire of tRNA-derived fragments in prostate cancer. |
| Q35248192 | A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer |
| Q46000370 | A prostate cancer susceptibility allele at 6q22 increases RFX6 expression by modulating HOXB13 chromatin binding. |
| Q57274821 | ANDROGEN RECEPTOR GENE AMPLIFICATION AT PRIMARY PROGRESSION PREDICTS RESPONSE TO COMBINED ANDROGEN BLOCKADE AS SECOND LINE THERAPY FOR ADVANCED PROSTATE CANCER |
| Q96576799 | AR and ERG drive the expression of prostate cancer specific long noncoding RNAs |
| Q51785008 | Activating mutation (V617F) in the tyrosine kinase JAK2 is absent in locally-confined or castration-resistant prostate cancer. |
| Q33700619 | Allelic variation at the 8q23.3 colorectal cancer risk locus functions as a cis-acting regulator of EIF3H. |
| Q36017026 | Alterations of androgen receptor in prostate cancer. |
| Q34127887 | Amplification and overexpression of Elongin C gene discovered in prostate cancer by cDNA microarrays. |
| Q35787051 | Amplification and overexpression of p40 subunit of eukaryotic translation initiation factor 3 in breast and prostate cancer. |
| Q24685619 | Amplification of EIF3S3 gene is associated with advanced stage in prostate cancer |
| Q38778571 | Amplification of the 9p13.3 chromosomal region in prostate cancer. |
| Q46906937 | Amplification of the urokinase gene and the sensitivity of prostate cancer cells to urokinase inhibitors. |
| Q37710893 | Analysis of spatial heterogeneity in normal epithelium and preneoplastic alterations in mouse prostate tumor models. |
| Q38673660 | Androgen Receptor Deregulation Drives Bromodomain-Mediated Chromatin Alterations in Prostate Cancer |
| Q37975896 | Androgen receptor (AR) aberrations in castration-resistant prostate cancer. |
| Q73341676 | Androgen receptor gene mutations in hormone-refractory prostate cancer |
| Q40420873 | Androgen receptor modifications in prostate cancer cells upon long-termandrogen ablation and antiandrogen treatment. |
| Q39644288 | Androgen regulation of micro-RNAs in prostate cancer |
| Q33357016 | Androgen regulation of the androgen receptor coregulators |
| Q42370830 | Appraising the relevance of DNA copy number loss and gain in prostate cancer using whole genome DNA sequence data |
| Q84156061 | Association of SPINK1 expression and TMPRSS2:ERG fusion with prognosis in endocrine-treated prostate cancer |
| Q48624908 | Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer |
| Q41071424 | Bcl-2 associated athanogene 5 (Bag5) is overexpressed in prostate cancer and inhibits ER-stress induced apoptosis. |
| Q59830543 | Biological aggressiveness of prostate cancer in the Finnish screening trial |
| Q36232068 | C/D-box snoRNA-derived RNA production is associated with malignant transformation and metastatic progression in prostate cancer |
| Q43948180 | CBX7 controls the growth of normal and tumor-derived prostate cells by repressing the Ink4a/Arf locus. |
| Q36260616 | CIP2A is a candidate therapeutic target in clinically challenging prostate cancer cell populations. |
| Q37533702 | Castration-resistant prostate cancer: from new pathophysiology to new treatment targets. |
| Q79400318 | Cellular changes in prostate cancer cells induced by intermittent androgen suppression |
| Q52829739 | Characterization of chromosomal abnormalities in prostate cancer cell lines by spectral karyotyping. |
| Q38326753 | Chemical castration and anti-androgens induce differential gene expression in prostate cancer. |
| Q28299365 | Chk1 targeting reactivates PP2A tumor suppressor activity in cancer cells |
| Q40215539 | Chromosomal aberrations in prostate cancer. |
| Q33634701 | Clinical association analysis of ependymomas and pilocytic astrocytomas reveals elevated FGFR3 and FGFR1 expression in aggressive ependymomas. |
| Q55477007 | Clinicopathological correlation of cell proliferation, apoptosis and p53 in cerebellar pilocytic astrocytomas. |
| Q74068217 | Complex chromosomal aberrations in chronic lymphocytic leukemia are associated with cellular drug and irradiation resistance |
| Q83807693 | Confirmation of the association of TMPRSS2(exon 0):ERG expression and a favorable prognosis of primary prostate cancer |
| Q30982222 | Construction of therapeutically relevant human prostate epithelial fate map by utilising miRNA and mRNA microarray expression data |
| Q34058710 | Contribution of ARLTS1 Cys148Arg (T442C) variant with prostate cancer risk and ARLTS1 function in prostate cancer cells |
| Q36497254 | Convergence of oncogenic and hormone receptor pathways promotes metastatic phenotypes |
| Q33730189 | Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer |
| Q38830273 | Copy number increase of oncoprotein CIP2A is associated with poor patient survival in human head and neck squamous cell carcinoma. |
| Q44294541 | DNA methylation signatures for prediction of biochemical recurrence after radical prostatectomy of clinically localized prostate cancer |
| Q34342466 | DOT1L-HES6 fusion drives androgen independent growth in prostate cancer |
| Q38967191 | Different gDNA content in the subpopulations of prostate cancer extracellular vesicles: apoptotic bodies, microvesicles, and exosomes |
| Q46068832 | Differential impact of RB status on E2F1 reprogramming in human cancer |
| Q40404439 | Dual-specificity phosphatase 1 and serum/glucocorticoid-regulated kinase are downregulated in prostate cancer. |
| Q81456373 | EZH2, Ki-67 and MCM7 are prognostic markers in prostatectomy treated patients |
| Q45183881 | Endometrial K-ras mutations in postmenopausal breast cancer patients treated with adjuvant tamoxifen or toremifene |
| Q36051801 | Epigenetically altered miR-193b targets cyclin D1 in prostate cancer |
| Q57274826 | Evidence for a prostate cancer susceptibility locus on the X chromosome. |
| Q24645931 | Expression and copy number analysis of TRPS1, EIF3S3 and MYC genes in breast and prostate cancer |
| Q43962349 | Expression of ERG oncoprotein is associated with a less aggressive tumor phenotype in Japanese prostate cancer patients. |
| Q28244019 | Expression of androgen receptor coregulators in prostate cancer |
| Q43492345 | Expression of epidermal growth factor receptor and ERBB2 (HER-2/Neu) oncoprotein in prostatic carcinomas |
| Q53779715 | Expressional profiling of prostate cancer risk SNPs at 11q13.5 identifies DGAT2 as a new target gene. |
| Q49562114 | Feasibility of Prostate PAXgene Fixation for Molecular Research and Diagnostic Surgical Pathology: Comparison of Matched Fresh Frozen, FFPE, and PFPE Tissues. |
| Q36606721 | Feature-based analysis of mouse prostatic intraepithelial neoplasia in histological tissue sections. |
| Q74620385 | Few FH mutations in sporadic counterparts of tumor types observed in hereditary leiomyomatosis and renal cell cancer families |
| Q34830129 | Generation of a conditionally replicating adenovirus based on targeted destruction of E1A mRNA by a cell type-specific MicroRNA. |
| Q83208558 | Genetic aberrations in prostate cancer by microarray analysis |
| Q39744507 | Genetic alterations and changes in expression of histone demethylases in prostate cancer. |
| Q74690618 | Genomewide DNA hypomethylation is associated with alterations on chromosome 8 in prostate carcinoma |
| Q74430826 | Gonadoblastoma and dysgerminoma associated with XY gonadal dysgenesis in an adolescent with chronic renal failure: a case of Frasier syndrome |
| Q38324695 | Goserelin and bicalutamide treatments alter the expression of microRNAs in the prostate. |
| Q44708071 | HOXB13 G84E mutation in Finland: population-based analysis of prostate, breast, and colorectal cancer risk |
| Q72326135 | High cell proliferation activity determined by DNA flow cytometry predicts poor prognosis after relapse in prostate cancer |
| Q39430806 | Histone H2B ubiquitin ligases RNF20 and RNF40 in androgen signaling and prostate cancer cell growth. |
| Q74128971 | Hormone-resistant prostate cancer with symptomatic pelvic tumours: patient survival and prognostic factors |
| Q73679093 | Human pHyde is not a classical tumor suppressor gene in prostate cancer |
| Q43550588 | Human prostate carcinoma cells as targets for herpes simplex virus thymidine kinase-mediated suicide gene therapy. |
| Q39003572 | Hypermethylation of the GABRE~miR-452~miR-224 promoter in prostate cancer predicts biochemical recurrence after radical prostatectomy |
| Q39983681 | Identification of ETS-like transcription factor 4 as a novel androgen receptor target in prostate cancer cells. |
| Q28140819 | Identification of novel transcription factor-like gene from human intestinal cells |
| Q42834135 | Identification of patients with transitional cell carcinoma of the bladder overexpressing ErbB2, ErbB3, or specific ErbB4 isoforms: real-time reverse transcription-PCR analysis in estimation of ErbB receptor status from cancer patients. |
| Q84453067 | Immunohistochemical ETS-related gene detection in a Japanese prostate cancer cohort: diagnostic use in Japanese prostate cancer patients |
| Q38489420 | Improved prognostic impact of S-phase values from paraffin-embedded breast and prostate carcinomas after correcting for nuclear slicing. |
| Q42359860 | Incidence of Mucinous Metaplasia in the Prostate of FVB/N Mice (Mus musculus). |
| Q38349829 | Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens. |
| Q38762493 | Inhibition of the glucocorticoid receptor results in an enhanced miR-99a/100-mediated radiation response in stem-like cells from human prostate cancers. |
| Q36859396 | Integrated clinical, whole-genome, and transcriptome analysis of multisampled lethal metastatic prostate cancer. |
| Q47925394 | In Vivo Expression of miR-32 Induces Proliferation in Prostate Epithelium |
| Q38904571 | Large-scale evaluation of SLC18A2 in prostate cancer reveals diagnostic and prognostic biomarker potential at three molecular levels |
| Q38174327 | Long noncoding RNA in prostate, bladder, and kidney cancer. |
| Q33862890 | Loss of PTEN is associated with aggressive behavior in ERG-positive prostate cancer |
| Q35227493 | Mapping of the chromosomal amplification 1p21-22 in bladder cancer |
| Q73821489 | Mapping the amplification of EIF3S3 in breast and prostate cancer |
| Q53088799 | Measuring the Expression of microRNAs Regulated by Androgens. |
| Q38904609 | MiR-1247-5p is overexpressed in castration resistant prostate cancer and targets MYCBP2. |
| Q58001257 | MicroRNA Expression Profile of Primary Prostate Cancer Stem Cells as a Source of Biomarkers and Therapeutic Targets |
| Q37836137 | MicroRNA in prostate, bladder, and kidney cancer: a systematic review. |
| Q35944835 | Microseminoprotein-Beta Expression in Different Stages of Prostate Cancer |
| Q35234637 | Mobile DNA in cancer. Extensive transduction of nonrepetitive DNA mediated by L1 retrotransposition in cancer genomes |
| Q58136321 | Molecular genetics of prostate cancer |
| Q77407356 | Molecular genetics of prostate cancer |
| Q80101555 | Molecular mechanisms of prostate cancer |
| Q43199043 | Mutation analysis of aryl hydrocarbon receptor interacting protein (AIP) gene in colorectal, breast, and prostate cancers |
| Q41261272 | Myc-dependent purine biosynthesis affects nucleolar stress and therapy response in prostate cancer. |
| Q74623236 | New pieces to the prostate cancer puzzle |
| Q67891079 | New studies on breast cancer to predict disease outcome and clinical use of these new tests |
| Q54855559 | No amplifications of hypoxia-inducible factor-1alpha gene in invasive breast cancer: a tissue microarray study. |
| Q83781921 | Novel endocrine aspects of prostate cancer |
| Q35212322 | Origins and functional consequences of somatic mitochondrial DNA mutations in human cancer |
| Q34042039 | Overall and worst gleason scores are equally good predictors of prostate cancer progression |
| Q40132834 | Overexpression and gene amplification of BAG-1L in hormone-refractory prostate cancer. |
| Q28248025 | PrLZ, a novel prostate-specific and androgen-responsive gene of the TPD52 family, amplified in chromosome 8q21.1 and overexpressed in human prostate cancer |
| Q73850937 | Predictors of biological aggressiveness of prostate specific antigen screening detected prostate cancer |
| Q43760304 | Prevalence and prognostic significance of TMPRSS2-ERG gene fusion in lymph node positive prostate cancers. |
| Q41412749 | Primary cutaneous T-cell lymphomas show a deletion or translocation affecting NAV3, the human UNC-53 homologue |
| Q67651198 | Prognostic value of analysis of DNA in pancreatic adenocarcinoma by flow cytometry |
| Q67524264 | Proliferative activity determined by DNA flow cytometry and proliferating cell nuclear antigen (PCNA) immunohistochemistry as a prognostic factor in prostatic carcinoma |
| Q100503866 | Prostate cancer evolution from multilineage primary to single lineage metastases with implications for liquid biopsy |
| Q33640983 | Prostate cancer risk regions at 8q24 and 17q24 are differentially associated with somatic TMPRSS2:ERG fusion status |
| Q28182316 | RAD21 and KIAA0196 at 8q24 are amplified and overexpressed in prostate cancer |
| Q35742514 | Recurrent SKIL-activating rearrangements in ETS-negative prostate cancer. |
| Q77551322 | Refined mapping of allele loss at chromosome 10q23-26 in prostate cancer |
| Q35690238 | Role of the chromobox protein CBX7 in lymphomagenesis. |
| Q57274851 | Small Subgroup of Aggressive, Highly Proliferative Prostatic Carcinomas Defined by p53 Accumulation |
| Q73426096 | Smoking and survival from lung cancer |
| Q53195350 | Somatic MED12 mutations in prostate cancer and uterine leiomyomas promote tumorigenesis through distinct mechanisms. |
| Q33369984 | Somatic mutation analysis of MYH11 in breast and prostate cancer |
| Q112302861 | Spatial analysis of histology in 3D: quantification and visualization of organ and tumor level tissue environment |
| Q36691140 | Stat3 promotes metastatic progression of prostate cancer. |
| Q38929732 | Statin use and risk of disease recurrence and death after radical prostatectomy. |
| Q37187362 | Statins and prostate cancer prevention: where we are now, and future directions. |
| Q81304490 | Steroids and prostate cancer |
| Q41511970 | Strong FGFR3 staining is a marker for FGFR3 fusions in diffuse gliomas. |
| Q39976204 | TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis. |
| Q38672122 | The Molecular Evolution of Castration-resistant Prostate Cancer |
| Q38710305 | The Potential of MicroRNAs as Prostate Cancer Biomarkers. |
| Q35548366 | The evolutionary history of lethal metastatic prostate cancer |
| Q47096576 | The expression of AURKA is androgen regulated in castration-resistant prostate cancer. |
| Q80860169 | The expression of SOCS is altered in rheumatoid arthritis |
| Q81580780 | The methyl-CpG-binding protein MECP2 is required for prostate cancer cell growth |
| Q39562536 | The miR-15a-miR-16-1 locus is homozygously deleted in a subset of prostate cancers |
| Q35579585 | The molecular genetics of prostate cancer. |
| Q26851631 | The mutational landscape of prostate cancer |
| Q38018444 | The role of genetic markers in the management of prostate cancer |
| Q36580474 | The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma |
| Q80438682 | Transcription factor Stat5 synergizes with androgen receptor in prostate cancer cells |
| Q38843095 | Transcriptome Sequencing Reveals PCAT5 as a Novel ERG-Regulated Long Noncoding RNA in Prostate Cancer. |
| Q39510855 | Tumor features and survival after radical prostatectomy among antidiabetic drug users |
| Q39066491 | USP22 regulates oncogenic signaling pathways to drive lethal cancer progression |
| Q84418995 | [Are there enough medical scientists in Finland?] |
| Q54724428 | cDNA microarray analysis of gene expression in coeliac disease jejunal biopsy samples. |
| Q39752124 | miR-193b is an epigenetically regulated putative tumor suppressor in prostate cancer. |
| Q38889145 | miR-25 Modulates Invasiveness and Dissemination of Human Prostate Cancer Cells via Regulation of αv- and α6-Integrin Expression. |
Search more.